Generic Spiriva Delivers First Mover Advantage In US, Lupin Plans Europe Launch

Lucentis Biosimilar Filing Seen In FY25

 
• By Vibha Ravi

Lupin’s Q2 margins jumped post launch of the first Spiriva generic in the US, encouraging launch plans for Europe and Canada. With four out of five plants clearing a regulatory overhang from earlier warning letters, the specialty engine is revving up though competition in first-to-file products launched earlier could dampen margins somewhat.

Growth Upward Trajectory
Lupin - On A Growth Trajectory • Source: Shutterstock

Lupin Limited’s Q2 FY24 earnings saw an anticipated boost to gross margins post the launch of a much-awaited first generic to Boehringer Ingelheim GmbH’s Spiriva Handihaler (tiotropium bromide) in the US in August.

Having achieved a 25% substitution rate, the company aspires to attain a steady state share of 35%-40% over a year or so given the low likelihood of competition for generic Spiriva (gSpiriva) in the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business